Translate this website into the following languages:

Close Tab
UC San Diego Health
menu iconMenu
search iconSearch

UC San Diego Moores Cancer Center New Member of National Comprehensive Cancer Network


March 20, 2013  |  

On March 19, the National Comprehensive Cancer Network® (NCCN®) announced the election of University of California, San Diego Moores Cancer Center as the first and only San Diego-based NCCN Member Institution dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer.

Moores Cancer Center 

UC San Diego Moores Cancer Center was elected as the first and only San Diego-based National Comprehensive Cancer Center Network Member Institution. 

“We are proud to join this prestigious alliance of the world’s leading cancer centers,” said Paul Viviano, CEO of UC San Diego Health System. “The physicians, scientists and clinicians of UC San Diego Moores Cancer Center and NCCN, share a vision of creating a healthier world, one life at a time, through new science, new medicine and new cures.”

As a NCCN Member Institution, UC San Diego Moores Cancer Center will be part of a national network that develops the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) used as the standard for clinical policy in oncology, incorporating expert medical judgment and recommendations of multidisciplinary panels from NCCN Member Institutions.

“The National Comprehensive Cancer Network and the UC San Diego Health System are bringing the most effective therapeutic and prevention strategies to cancer patients,” said Scott M. Lippman, MD, director of the Moores Cancer Center. “We look forward to working with fellow premier NCCN institutions to impact the outcomes of cancer care and to influence the direction of the cancer field.”

Joining 22 other institution members of NCCN, Moores Cancer Center was selected because of its role in transforming cancer care and providing exceptional care to cancer patients. Moores Cancer Center is the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in the San Diego region. Its multi-disciplinary team approach includes translating the basic scientific discoveries of its research faculty into new treatments for cancer patients in the clinic.

“We are extremely pleased that UC San Diego Moores Cancer Center has been elected to institutional membership in the NCCN,” said Robert Carlson, MD, CEO of the National Comprehensive Cancer Network. “Moores Cancer Center adds substantial strength and expertise to the excellence of cancer care, research, and education characteristic of the other world-class member institutions.”

About the National Comprehensive Cancer Network®
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world’s leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

# # #

Media Contact: Yadira Galindo, 619-543-6163,

Related Specialties


Media Contact

Share This Article

Related News

Rock star drummer Rikki Rockett feels very lucky to be on tour with his band, Poison. A year ago, he didn’t know if he would survive tongue cancer but after participating in an immunotherapy clinical ...
The Leapfrog Group, a nonprofit organization that advocates quality, safety and transparency in the U.S. health care system, has named UC San Diego Health to its biannual list of hospitals with the hi ...
Genetic mutations that cause cancer also weaken cancer cells, allowing researchers to develop drugs that will selectively kill them. This is called “synthetic lethality” because the drug is only letha ...
A team of 18 University of California San Diego School of Medicine and Moores Cancer Center researchers has developed a new tool to analyze an often overlooked aspect of cancer genetics — an alteratio ...

Follow Us

Our bimonthly newsletter delivers healthy lifestyle tips, patient stories and research discovery news. Subscribe: